The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2020 | Myeloma transplantation: 17p deletions & 4;14 translocations
Nico Gagelmann, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses the findings from a Chronic Malignancies Working Party European Blood and Marrow Transplant (CMWP-EBMT) study evaluating upfront stem cell transplantation for newly diagnosed multiple myeloma with 17p deletions and 4;14 translocations. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
